TITLE

Robust blood market

AUTHOR(S)
Lee, Jaimy
PUB. DATE
June 2011
SOURCE
Modern Healthcare;6/6/2011, Vol. 41 Issue 23, p14
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the divestiture requirement imposed by the U.S. Federal Trade Commission (FTC) on the acquisition deal between Grifols and Talecris Biotherapeutics. A number of plasma collection centers across the U.S. will be divested by Grifols as part of the FTC settlement. Also, Grifols is required to partner with Kedrion, another rival in the blood-plasma products market. Bill Woodward of Novation believes that the Grifols-Talecris deal would positively impact pricing in the market.
ACCESSION #
61141501

 

Related Articles

  • Bayer and Aventis Confirm Plasma Products Merger. Mullin, Rick; Young, Ian // Chemical Week;2/27/2002, Vol. 164 Issue 8, p18 

    Reports on the merger of blood plasma businesses, Bayer Biological Products and Aventis Behring. Terms of the joint venture; Executives that are appointed to manage the merged company; Key products of the blood plasma businesses.

  • Neutralizing antibodies in survivors of Sin Nombre and Andes hantavirus infection. Valdivieso, Francisca; Vial, Pablo; Ferres, Marcela; Ye, Chunyan; Goade, Diane; Cuiza, Analia; Hjelle, Brian // Emerging Infectious Diseases;Jan2006, Vol. 12 Issue 1, p166 

    We evaluated titers of homotypic and heterotypic neutralizing antibodies (NAbs) to Andes and Sin Nombre hantaviruses in plasma samples from 20 patients from Chile and the United States. All but 1 patient had high titers of NAb. None of the plasma samples showed high titers against the...

  • Therapeutic antibodies: the next generation. Aldridge, Susan // Pharmaceutical Technology Europe;May2009, Vol. 21 Issue 5, p36 

    The article focuses on the significance of manufacturing technology for the increasing number of therapeutic antibodies. It mentions that an inter-biotech merger is the less preferred strategy to link up with other pharmaceutical companies that can offer greater sales. It notes that Big Pharma's...

  • Despite M&A, fine chems find niche. Mirasol, Feliza // Chemical Market Reporter;5/15/2006, Vol. 269 Issue 19, p34 

    The article looks at trends in the fine chemicals sector as of May 2006. The mergers of large branded and generic pharmaceutical companies have negatively affected fine chemical manufacturers because the combined companies have built their own manufacturing facilities. A chart showing the top...

  • Expansion through competition.  // Pharmaceutical Technology Europe;Nov2005, Vol. 17 Issue 11, p12 

    Focuses on the expansion of Gerresheimer company in the U.S. following an acquisition involving former competitors. Plans to take over the container glass works of Glass Group Inc. in Millville; Share gained by Gerresheimer Inc. from competitors in the Chinese specialty glass manufacturer...

  • STRATEGIC ANALYSIS OF THE WORLD PHARMACEUTICAL INDUSTRY. Kesič, Dragan // Management: Journal of Contemporary Management Issues;Jun2009, Vol. 14 Issue 1, p59 

    The world pharmaceutical industry has been changing profoundly in the last decade. Intensive globalization, increased competitiveness and the fight for global market shares create new challenges for pharmaceutical companies. Fast globalization definitively reinforces the consolidation of the...

  • Indian API producers going global. Jarvis, Lisa // European Chemical News;10/31/2005, Vol. 83 Issue 2169, p29 

    This article reports that Indian active pharmaceutical ingredients (API) companies are starting to look beyond their borders and are eyeing up prospects in the U.S. and Europe as of October 2005. Indian API manufacturers are not only challenging long-established U.S. and European fine chemicals...

  • The new battle for market share intensifies. Lisanti, Tony // Drug Store News;4/5/2004, Vol. 26 Issue 5, p13 

    Focuses on the increase in competition in the retail pharmacy sector in the U.S. Competition faced by drug stores from supermarkets with drug retail operations; Mergers and consolidation deals affecting the industry; Implications for drug store chains.

  • Prospecting for next goldmine. Thomaselli, Rich // Advertising Age;11/15/2004, Vol. 75 Issue 46, p40 

    Reports on the status of Pfizer in the pharmaceutical industry as of November 2004. Information on the acquired marketers of the company; Impact of the loss of patent protection of major drugs on genetic competition and sales; Information on the financial performance of the company in 2004.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics